{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:59:11Z","timestamp":1740110351539,"version":"3.37.3"},"reference-count":6,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002749","name":"Belgian Science Policy Office","doi-asserted-by":"publisher","award":["IAP-P7\/45 BELVIR"],"award-info":[{"award-number":["IAP-P7\/45 BELVIR"]}],"id":[{"id":"10.13039\/501100002749","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.antiviral.2017.11.010","type":"journal-article","created":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T20:01:07Z","timestamp":1510689667000},"page":"150-153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rational design of antiviral drug combinations based on equipotency using HCV subgenomic replicon as an in vitro model"],"prefix":"10.1016","volume":"149","author":[{"given":"Mohamed","family":"Mandour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge","family":"Vliegen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Paeshuyse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Neyts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2017.11.010_bib1","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1128\/AAC.00294-11","article-title":"Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication","volume":"55","author":"Delang","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2017.11.010_bib2","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nbt.2020","article-title":"Discovery and development of telaprevir: an NS3\u20134A protease inhibitor for treating genotype 1 chronic hepatitis C virus","volume":"29","author":"Kwong","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2017.11.010_bib3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.antiviral.2017.02.014","article-title":"Current therapy for chronic hepatitis C: the role of direct-acting antivirals","volume":"142","author":"Li","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.11.010_bib4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1872-034X.2012.01056.x","article-title":"A multicenter survey of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan","volume":"43","author":"Oze","year":"2013","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.antiviral.2017.11.010_bib5","doi-asserted-by":"crossref","first-page":"4432","DOI":"10.1128\/AAC.00699-08","article-title":"Preclinical characteristics of the hepatitis C virus NS3\/4A protease inhibitor ITMN-191 (R7227)","volume":"52","author":"Seiwert","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2017.11.010_bib6","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jhep.2008.12.028","article-title":"Substituted imidazopyridines as potent inhibitors of HCV replication","volume":"50","author":"Vliegen","year":"2009","journal-title":"J. Hepatol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217304199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217304199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T14:53:03Z","timestamp":1575384783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354217304199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":6,"alternative-id":["S0166354217304199"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.11.010","relation":{},"ISSN":["0166-3542"],"issn-type":[{"type":"print","value":"0166-3542"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rational design of antiviral drug combinations based on equipotency using HCV subgenomic replicon as an in vitro model","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}